01—Abstract
Summary
Summary of the 10-Q filed May 2, 2024. Cited figures are marked; the original filing is the authoritative source.
Cardinal Health Inc. reported solid revenue growth in the third quarter of fiscal year 2024, with total revenue increasing by 9% year-over-year to $54.9 billiona.
This growth was primarily driven by increased branded and specialty pharmaceutical sales within its Pharmaceutical and Specialty Solutions segment. While GAAP operating earnings saw a decline primarily due to litigation charges and goodwill impairment, the company's non-GAAP operating earnings showed significant improvement, increasing by 10% to $666 millionb. This highlights the company's operational performance excluding certain non-recurring or significant charges.
Despite ongoing challenges, including significant litigation expenses and a goodwill impairment charge related to the GMPD segment, Cardinal Health demonstrated strong operational execution. The company's strategic acquisition of Specialty Networks for $1.2 billionc aims to enhance its data analytics capabilities and expand its offerings in key therapeutic areas.
However, investors should note the upcoming non-renewal of contracts with OptumRx, which represented 16%d of fiscal year 2023 revenue, posing a significant headwind for fiscal year 2025. The company is actively managing its capital through share repurchases and dividends while maintaining adequate liquidity.
02—Key points
Key Highlights
- Revenue increased by 9% to $54.9 billion for the three months ended March 31, 2024, driven by the Pharmaceutical and Specialty Solutions segment.
- Non-GAAP operating earnings grew by 10% to $666 million for the quarter, indicating improved underlying business performance.
- GAAP operating earnings decreased by 36% to $367 million, largely impacted by litigation charges and a $90 million goodwill impairment.
- Acquisition of Specialty Networks for $1.2 billion completed in March 2024 to expand data analytics and biopharma offerings.
- Significant impact from the upcoming non-renewal of pharmaceutical distribution contracts with OptumRx, which accounted for 16% of FY2023 revenue, expected to impact FY2025 results.
- Cash and equivalents stood at $3.7 billion, with $1.7 billion in net cash provided by operating activities for the nine months ended March 31, 2024.
- The company returned $750 million to shareholders through share repurchases and paid $377 million in dividends during the nine months ended March 31, 2024.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q3 FY2024, Cardinal Health Inc kept $0.00.
- Revenue$54.87B100.0%
- Cost of revenue−$52.93B96.5%
- Gross profit$1.94B3.5%
- Operating costs−$1.57B2.9%
- Operating income$369.0M0.7%
- Interest, other & tax−$108.0M0.2%
- Net income$261.0M0.5%
04—Financials
Financial Highlights
Figures from 10-QQ3 FY2024filed May 2, 2024Financial Statements
Q3 FY2024 against Q3 FY2023
| Line item | Q3 FY2024Q3 FY2023 | Change |
|---|---|---|
| Revenue | $54.87B$50.50B | +8.7% |
| Cost of Revenue | $52.93B$48.69B | +8.7% |
| Gross Profit | $1.94B$1.81B | +6.9% |
| SG&A Expenses | $1.27B$1.17B | +8.3% |
| Operating Income | $369.00M$604.00M | −38.9% |
| Interest Expense | $28.00M$26.00M | +7.7% |
| Net Income | $261.00M$365.00M | −28.5% |
| EPS (Basic) | $1.07$1.43 | −25.2% |
| EPS (Diluted) | $1.07$1.41 | −24.1% |
| Shares Outstanding (Basic) | 243.00M256.00M | −5.1% |
| Shares Outstanding (Diluted) | 245.00M258.00M | −5.0% |
05—Questions
Frequently Asked Questions
What is the impact of the OptumRx contract non-renewal on Cardinal Health's future performance?
The non-renewal of pharmaceutical distribution contracts with OptumRx, which expire at the end of June 2024, is expected to adversely impact Cardinal Health's results of operations, including segment profit, financial condition, and cash flows, particularly in fiscal year 2025. This is due to OptumRx representing 16% of consolidated revenue in fiscal year 2023, and the unwinding of negative net working capital associated with these contracts.
How did litigation and goodwill impairment affect reported earnings?
Both litigation charges and goodwill impairments significantly impacted GAAP operating earnings and EPS. For the three months ended March 31, 2024, litigation charges of $193 million (partially offset by a benefit) and a $90 million goodwill impairment charge related to the GMPD segment were recognized. These items, along with others, are excluded from non-GAAP operating earnings, which showed a 10% increase.
What is the strategic rationale behind the Specialty Networks acquisition?
The acquisition of Specialty Networks for $1.2 billion is intended to expand Cardinal Health's offerings in key therapeutic areas, accelerate upstream data and research opportunities with biopharma manufacturers, and create a platform for further expansion. Specialty Networks utilizes AI and data analytics to provide insights for independent specialty providers.
What is the current liquidity and capital position of Cardinal Health?
As of March 31, 2024, Cardinal Health had $3.7 billion in cash and equivalents. For the nine months ended March 31, 2024, the company generated $1.7 billion in net cash from operating activities. The company also has access to a $2.0 billion commercial paper program and a $2.0 billion revolving credit facility, with no amounts outstanding under these facilities as of the reporting date. Capital was deployed for the Specialty Networks acquisition, share repurchases, and dividends.
06—Continue